Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0EC2K
|
||||
Former ID |
DNC009423
|
||||
Drug Name |
SIPATRIGINE
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Neurological disease [ICD9: 338, 338.2, 410, 782.3,780; ICD10:I21, I22, R52, R52.1-R52.2, R60.9, G89] | Discontinued in Phase 2 | [545614] | ||
Structure |
Download2D MOL |
||||
Formula |
C15H16Cl3N5
|
||||
Canonical SMILES |
CN1CCN(CC1)C2=NC=C(C(=N2)N)C3=CC(=CC(=C3Cl)Cl)Cl
|
||||
InChI |
1S/C15H16Cl3N5/c1-22-2-4-23(5-3-22)15-20-8-11(14(19)21-15)10-6-9(16)7-12(17)13(10)18/h6-8H,2-5H2,1H3,(H2,19,20,21)
|
||||
InChIKey |
PDOCBJADCWMDGL-UHFFFAOYSA-N
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | Voltage-dependent L-type calcium channel alpha-1D subunit | Target Info | Inhibitor | [551286] | |
Voltage-gated sodium channel subunit alpha Nav1.3 | Target Info | Inhibitor | [526398] | ||
Sodium channel | Target Info | Inhibitor | [525961] | ||
Sodium channel protein type 4 subunit alpha | Target Info | Inhibitor | [530055] | ||
Sodium channel protein type 5 subunit alpha | Target Info | Inhibitor | [525961] | ||
Voltage-gated sodium channel subunit alpha Nav1.7 | Target Info | Inhibitor | [530055] | ||
Voltage-gated sodium channel subunit alpha Nav1.8 | Target Info | Inhibitor | [530055] | ||
KEGG Pathway | MAPK signaling pathway | ||||
Calcium signaling pathway | |||||
cGMP-PKG signaling pathway | |||||
cAMP signaling pathway | |||||
Cardiac muscle contraction | |||||
Adrenergic signaling in cardiomyocytes | |||||
Vascular smooth muscle contraction | |||||
Circadian entrainment | |||||
Retrograde endocannabinoid signaling | |||||
Glutamatergic synapse | |||||
Cholinergic synapse | |||||
Serotonergic synapse | |||||
GABAergic synapse | |||||
Dopaminergic synapse | |||||
Insulin secretion | |||||
GnRH signaling pathway | |||||
Oxytocin signaling pathway | |||||
Type II diabetes mellitus | |||||
Carbohydrate digestion and absorption | |||||
Alzheimer's disease | |||||
Amphetamine addiction | |||||
Hypertrophic cardiomyopathy (HCM) | |||||
Arrhythmogenic right ventricular cardiomyopathy (ARVC) | |||||
Dilated cardiomyopathyhsa04728:Dopaminergic synapsehsa04261:Adrenergic signaling in cardiomyocytes | |||||
PathWhiz Pathway | Muscle/Heart Contraction | ||||
Reactome | Adrenaline,noradrenaline inhibits insulin secretion | ||||
NCAM1 interactions | |||||
Regulation of insulin secretionR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and AnkyrinsR-HSA-445095:Interaction between L1 and Ankyrins | |||||
References | |||||
Ref 525961 | J Med Chem. 2001 Jan 18;44(2):115-37.Medicinal chemistry of neuronal voltage-gated sodium channel blockers. | ||||
Ref 526398 | J Med Chem. 2002 Aug 15;45(17):3755-64.Synthesis and structure-activity relationships of 6,7-benzomorphan derivatives as use-dependent sodium channel blockers for the treatment of stroke. | ||||
Ref 530055 | J Med Chem. 2009 May 14;52(9):2694-707.Oxadiazolylindazole sodium channel modulators are neuroprotective toward hippocampal neurones. | ||||
Ref 551286 | Synthesis and characterization of N-(acenaphth-5-yl)-N'-(4-methoxynaphth-1-yl)guanidine as a glutamate release inhibitor and potential anti-ischemic agent, Bioorg. Med. Chem. Lett. 5(19):2259-2262 (1995). |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.